[1] European Association for the Study of the Liver. EASL clinical practice guidelines:Drug-induced liver injury[J]. J Hepatol,2019,70(6):1222-1261.
|
[2] SHEN T,LIU Y,SHANG J,et al. Incidence and etiology of drug-induced liver injury in mainland China[J]. Gastroenterology,2019,156(8):2230-2241.
|
[3] LI C,RAO T,CHEN X,et al. HLA-B*35∶01 allele is a potential biomarker for predicting polygonum multiflorum-induced liver injury in humans[J]. Hepatology,2019,70(1):346-357.
|
[4] OU P,LIU X,TANG Z,et al. Gynura segetum related hepatic sinusoidal obstruction syndrome:A liver disease with high mortality and misdiagnosis rate[J]. Curr Pharm Des,2019.[Epub ahead of print]
|
[5] ZHUGE Y,LIU Y,XIE W,et al. Expert consensus on the clinical management of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome[J]. J Gastroenterol Hepatol,2019,34(4):634-642.
|
[6] YU YC,MAO YM,CHEN CW,et al. CSH guidelines for the diagnosis and treatment of drug-induced liver injury[J]. Hepatol Int,2017,11(3):221-241.
|
[7] CHALASANI NP,HAYASHI PH,BONKOVSKY HL,et al. ACG clinical guideline:The diagnosis and management of idiosyncratic drug-induced liver injury[J]. Am J Gastroenterol,2014,109(7):950-966.
|
[8] Branch of Hepatobiliary Diseases,China Association of Chinese Medicine; Branch of Chinese Patent Medicine,China Association of Chinese Medicine. Guideline for diagnosis and treatment of herb-induced liver injury[J]. J Clin Hepatol,2016,32(5):835-843.(in Chinese)中华中医药学会肝胆病分会,中华中医药学会中成药分会.中草药相关肝损伤临床诊疗指南[J].临床肝胆病杂志,2016,32(5):835-843.
|